B+
Bull case
25%
Probability
Target price
$9.50
+81.0% vs current
SVRA
SavaraDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$5.40
+2.9% vs current
B-
Bear case
30%
Probability
Target price
$3.00
-42.9% vs current
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+57.6
Score
AI commentary
Sentiment is cautious rather than outright bearish: recent company updates kept the program alive and de-risked some procedural concerns, but the April 15, 2026 review extension weakened near-term momentum and reinforced that SVRA is still a monitoring-style regulatory trade. The evidence quality is high because the setup is confirmed by company and SEC materials, yet forward visibility is still narrow because nearly all upside and downside concentrate around one FDA outcome.
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-17catalystATS 2026 presentations could shape sentiment ahead of the FDA decisionHigh impact
Savara announced on April 14, 2026 that ATS presentations on May 17-20, 2026 will include new Phase 3 IMPALA-2 data, including open-label treatment-period results and biomarker analyses; for a low-coverage name, supportive read-through could help sentiment, but conference data are usually secondary to the regulatory path [#PR-2026-04-14].
2026-11-22catalystFDA action on molgramostim BLA now due November 22, 2026High impact
Savara said on April 15, 2026 that FDA extended Priority Review by three months after treating the company’s responses to information requests as a major amendment, moving the PDUFA date to November 22, 2026; the same release said FDA did not cite safety, efficacy, or manufacturing concerns, but the extension pushes out the key value-creation event for this single-asset story [#PR-2026-04-15].
2026-11-22catalystLaunch-funding overhang is partly reduced if MOLBREEVI is approvedHigh impact
Savara’s 2025 Form 10-K said it had $235.7 million of cash, cash equivalents, and short-term investments at December 31, 2025 and may borrow up to an additional $75 million under the amended Hercules facility upon FDA approval; the January 27, 2026 company release also framed that facility plus prior royalty financing as roughly $150 million of non-dilutive launch capital, which helps limit financing pressure but does not remove the binary dependence on approval [#10-K-2026-03-13] [#PR-2026-01-27].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology